The impact of simvastatin on warfarin disposition and dose requirements

J Thromb Haemost. 2006 Jun;4(6):1422-4. doi: 10.1111/j.1538-7836.2006.01974.x.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage*
  • Anticoagulants / pharmacokinetics
  • Aryl Hydrocarbon Hydroxylases / antagonists & inhibitors
  • Blood Coagulation / drug effects
  • Cytochrome P-450 CYP2C9
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme Inhibitors
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Liver / drug effects
  • Liver / enzymology
  • Male
  • Middle Aged
  • Simvastatin / administration & dosage
  • Simvastatin / pharmacology*
  • Warfarin / administration & dosage*
  • Warfarin / pharmacokinetics

Substances

  • Anticoagulants
  • Cytochrome P-450 Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Warfarin
  • Simvastatin
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human